Proteome Analysis of Urinary Biomarkers in a Cigarette Smoke-induced COPD Rat Model

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2022 Jun 15

PMID 35705945

Authors

Weiwei Qin

He Huang

Yuting Dai

Wei Han

Youhe Gao

Affiliations

Soon will be listed here.

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory airway disease caused by inhalation of cigarette smoke (CS) and other harmful gases and particles.

Methods: This study aimed to explore potential urinary biomarkers for CS-induced COPD based on LC-MS/MS analysis.

Results: A total of 340 urinary proteins were identified, of which 79 were significantly changed (30, 31, and 37 at week 2, 4 and 8, respectively). GO annotation of the differential urinary proteins revealed that acute-phase response, response to organic cyclic compounds, complement activation classical pathway, and response to lead ion were significantly enriched at week 2 and 4. Another four processes were only enriched at week 8, namely response to oxidative stress, positive regulation of cell proliferation, thyroid hormone generation, and positive regulation of apoptotic process. The PPI network indicated that these differential proteins were biologically connected in CS-exposed rats. Of the 79 differential proteins in CS-exposed rats, 56 had human orthologs. Seven proteins that had changed at week 2 and 4 when there were no changes of pulmonary function and pathological morphology were verified as potential biomarkers for early screening of CS-induced COPD by proteomic analysis. Another six proteins that changed at week 8 when obvious airflow obstruction was detected were verified as potential biomarkers for prognostic assessment of CS-induced COPD.

Conclusions: These results reveal that the urinary proteome could sensitively reflect pathological changes in CS-exposed rats, and provide valuable clues for exploring COPD biomarkers.

Citing Articles

Urinary Proteome and Exosome Analysis Protocol for the Discovery of Respiratory Diseases Biomarkers.

Martelo-Vidal L, Vazquez-Mera S, Miguens-Suarez P, Bravo-Lopez S, Makrinioti H, Dominguez-Arca V Biomolecules. 2025; 15(1).

PMID: 39858454 PMC: 11762655. DOI: 10.3390/biom15010060.

Moderate-intensity physical activity reduces the role of serum PFAS on COPD: A cross-sectional analysis with NHANES data.

Pan M, Zou Y, Wei G, Zhang C, Zhang K, Guo H PLoS One. 2024; 19(8):e0308148.

PMID: 39110698 PMC: 11305543. DOI: 10.1371/journal.pone.0308148.

Urinary protein changes during the short-term growth and development of rats.

Liu Y, Yang M, Wang H, Chen Y, Gao Y Heliyon. 2024; 10(3):e24555.

PMID: 38317946 PMC: 10839868. DOI: 10.1016/j.heliyon.2024.e24555.

A Pilot Urinary Proteome Study Reveals Widespread Influences of Circadian Rhythm Disruption by Sleep Deprivation.

Zhou L, Lu X, Wang X, Huang Z, Wu Y, Zhou L Appl Biochem Biotechnol. 2023; 196(4):1992-2011.

PMID: 37458940 DOI: 10.1007/s12010-023-04666-9.

Prognostic Biomarkers Based on Proteomic Technology in COPD: A Recent Review.

Fang H, Liu Y, Yang Q, Han S, Zhang H Int J Chron Obstruct Pulmon Dis. 2023; 18:1353-1365.

PMID: 37408604 PMC: 10319291. DOI: 10.2147/COPD.S410387.

References

Kuk C, Gunawardana C, Soosaipillai A, Kobayashi H, Li L, Zheng Y . Nidogen-2: a new serum biomarker for ovarian cancer. Clin Biochem. 2009; 43(4-5):355-61. PMC: 3109863. DOI: 10.1016/j.clinbiochem.2009.10.012. View

Hashimoto N, Wakahara K, Sakamoto K . The Importance of Appropriate Diagnosis in the Practical Management of Chronic Obstructive Pulmonary Disease. Diagnostics (Basel). 2021; 11(4). PMC: 8067197. DOI: 10.3390/diagnostics11040618. View

Limper A, Roman J . Fibronectin. A versatile matrix protein with roles in thoracic development, repair and infection. Chest. 1992; 101(6):1663-73. DOI: 10.1378/chest.101.6.1663. View

Ashburner M, Ball C, Blake J, Botstein D, Butler H, Cherry J . Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25(1):25-9. PMC: 3037419. DOI: 10.1038/75556. View

Zhu C, Jiang L, Xu J, Ren A, Ju F, Shu Y . The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma. Pathol Res Pract. 2020; 216(4):152885. DOI: 10.1016/j.prp.2020.152885. View

Li F, Xu D, Wang J, Jing J, Li Z, Jin X . Comparative proteomics analysis of patients with quick development and slow development Chronic Obstructive Pulmonary Disease (COPD). Life Sci. 2020; 256:117829. DOI: 10.1016/j.lfs.2020.117829. View

Lange P, Ahmed E, Lahmar Z, Martinez F, Bourdin A . Natural history and mechanisms of COPD. Respirology. 2021; 26(4):298-321. DOI: 10.1111/resp.14007. View

Wu D, Zhang S, Xie Z, Chen E, Rao Q, Liu X . Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. J Clin Invest. 2020; 130(4):2069-2080. PMC: 7108894. DOI: 10.1172/JCI130197. View

Jahan R, Ganguly K, Smith L, Atri P, Carmicheal J, Sheinin Y . Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. EBioMedicine. 2019; 42:375-385. PMC: 6491718. DOI: 10.1016/j.ebiom.2019.03.056. View

10.

Man S, Xing L, Connett J, Anthonisen N, Wise R, Tashkin D . Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?. Eur Respir J. 2008; 32(6):1451-7. DOI: 10.1183/09031936.00153207. View

11.

Solimando A, Brandl A, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A . JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia. 2017; 32(3):736-743. PMC: 5843918. DOI: 10.1038/leu.2017.287. View

12.

Jahan R, Shah A, Kisling S, Macha M, Thayer S, Batra S . Odyssey of trefoil factors in cancer: Diagnostic and therapeutic implications. Biochim Biophys Acta Rev Cancer. 2020; 1873(2):188362. DOI: 10.1016/j.bbcan.2020.188362. View

13.

Mosesson M, Amrani D . The structure and biologic activities of plasma fibronectin. Blood. 1980; 56(2):145-58. View

14.

Zhang Y, Xiao W, Jiang Y, Wang H, Xu X, Ma D . Levels of components of the urokinase-type plasminogen activator system are related to chronic obstructive pulmonary disease parenchymal destruction and airway remodelling. J Int Med Res. 2012; 40(3):976-85. DOI: 10.1177/147323001204000316. View

15.

Schuliga M, Westall G, Xia Y, Stewart A . The plasminogen activation system: new targets in lung inflammation and remodeling. Curr Opin Pharmacol. 2013; 13(3):386-93. DOI: 10.1016/j.coph.2013.05.014. View

16.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. PMC: 10790329. DOI: 10.1016/S0140-6736(12)61728-0. View

17.

Qin W, Wang T, Liu G, Sun L, Han W, Gao Y . Dynamic Urinary Proteome Changes in Ovalbumin-Induced Asthma Mouse Model Using Data-Independent Acquisition Proteomics. J Asthma Allergy. 2021; 14:1355-1366. PMC: 8590963. DOI: 10.2147/JAA.S330054. View

18.

Wang Q, Wang Y, Zhang Y, Zhang Y, Xiao W . Involvement of urokinase in cigarette smoke extract-induced epithelial-mesenchymal transition in human small airway epithelial cells. Lab Invest. 2015; 95(5):469-79. DOI: 10.1038/labinvest.2015.33. View

19.

Viby N, Pedersen L, Lund T, Kissow H, Backer V, Nexo E . Trefoil factor peptides in serum and sputum from subjects with asthma and COPD. Clin Respir J. 2014; 9(3):322-9. DOI: 10.1111/crj.12146. View

20.

Lee C, Im E, Moon P, Baek M . Discovery of a diagnostic biomarker for colon cancer through proteomic profiling of small extracellular vesicles. BMC Cancer. 2018; 18(1):1058. PMC: 6211419. DOI: 10.1186/s12885-018-4952-y. View